Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Epizyme Inc (NASDAQ:EPZM)

20.10
Delayed Data
As of Aug 28
 +2.60 / +14.86%
Today’s Change
13.67
Today|||52-Week Range
35.50
+6.52%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$830.7M

Company Description

Epizyme, Inc. operates as a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. It is engaged in the creation of small molecule histone methyltransferase inhibitors, a new class of personalized therapeutics for the treatment of patients with genetically defined cancers, based on breakthroughs in the field of epigenetics. Epizyme was founded by H. Robert Horvitz and Yi Zhang on November 1, 2007 and is headquartered in Cambridge, MA.

Contact Information

Epizyme, Inc.
400 Technology Square
Cambridge Massachusetts 02139
P:(617) 229-5872
Investor Relations:

Employees

Shareholders

Individual stakeholders47.07%
Mutual fund holders45.37%
Other institutional19.68%

Top Executives

Robert J. GouldPresident, CEO, Secretary & Director
Stephen GarbaczExecutive Director-Finance
Andrew E. SingerCFO, Treasurer & Executive VP-Administration
Robert A. CopelandPresident-Research & Chief Scientific Officer
Tai-Ching HoChief Development Officer